Research ExplorerPublicationsExpression of CEACAM1 in adenocarcinoma of the lung

Expression of CEACAM1 in adenocarcinoma of the lung

Standard

Expression of CEACAM1 in adenocarcinoma of the lung : a factor of independent prognostic significance. / Laack, Eckart; Nikbakht, Haleh; Peters, Anja; Kugler, Christian; Jasiewicz, Yvonne; Edler, Lutz; Brümmer, Jens; Schumacher, Udo; Hossfeld, Dieter Kurt.

In: J CLIN ONCOL, Vol. 20, No. 21, 01.11.2002, p. 4279-84.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laack, E, Nikbakht, H, Peters, A, Kugler, C, Jasiewicz, Y, Edler, L, Brümmer, J, Schumacher, U & Hossfeld, DK 2002, 'Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance', J CLIN ONCOL, vol. 20, no. 21, pp. 4279-84.

APA

Laack, E., Nikbakht, H., Peters, A., Kugler, C., Jasiewicz, Y., Edler, L., Brümmer, J., Schumacher, U., & Hossfeld, D. K. (2002). Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J CLIN ONCOL, 20(21), 4279-84.

Vancouver

Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J CLIN ONCOL. 2002 Nov 1;20(21):4279-84.

Bibtex

@article{5d46303d36a640c497d3d4b0ac6ec21e,
title = "Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance",
abstract = "PURPOSE: To evaluate the prognostic relevance of CEACAM1 and sialyl Lewis X expression in adenocarcinomas of the lung.PATIENTS AND METHODS: Paraffin wax sections of 93 patients with adenocarcinomas of the lung who underwent surgery between 1990 and 1995 were immunohistochemically investigated using monoclonal anti-CEACAM1 and sialyl Lewis X antibodies. The clinical course of all patients was followed up for a minimum of 5 years.RESULTS: Sixty-one tumors were classified as CEACAM1-positive, and 32 were classified as CEACAM1-negative. Patients with CEACAM1-positive tumors had a significantly poorer overall (P =.00025) and relapse-free (P =.00029) survival than those with CEACAM1-negative tumors. Only three patients did not express the sialyl Lewis X glycotope, whereas 90 tumors (97%) were sialyl Lewis X-positive. In multivariate Cox regression analysis, next to tumor stage and sex, only the expression of CEACAM1 was a significant independent prognostic factor for survival.CONCLUSION: Expression of CEACAM1 was an independent prognostic factor in our patient population and can be used to stratify patients with adenocarcinomas of the lung into low-risk and high-risk groups. In contrast, the expression of sialyl Lewis X was of no prognostic relevance because it was expressed in 97% of all investigated tumors, and most likely has no influence on the function of CEACAM1 in this tumor entity.",
keywords = "Adenocarcinoma, Adult, Aged, Antibodies, Monoclonal, Antigens, CD, Antigens, CD15, Antigens, Differentiation, Carcinoma, Non-Small-Cell Lung, Cell Adhesion Molecules, Female, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Lewis Blood-Group System, Lung Neoplasms, Male, Middle Aged, Oligosaccharides, Prognosis, Retrospective Studies, Risk Factors, Survival Analysis, Tumor Markers, Biological",
author = "Eckart Laack and Haleh Nikbakht and Anja Peters and Christian Kugler and Yvonne Jasiewicz and Lutz Edler and Jens Br{\"u}mmer and Udo Schumacher and Hossfeld, {Dieter Kurt}",
year = "2002",
month = nov,
day = "1",
language = "English",
volume = "20",
pages = "4279--84",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

RIS

TY - JOUR

T1 - Expression of CEACAM1 in adenocarcinoma of the lung

T2 - a factor of independent prognostic significance

AU - Laack, Eckart

AU - Nikbakht, Haleh

AU - Peters, Anja

AU - Kugler, Christian

AU - Jasiewicz, Yvonne

AU - Edler, Lutz

AU - Brümmer, Jens

AU - Schumacher, Udo

AU - Hossfeld, Dieter Kurt

PY - 2002/11/1

Y1 - 2002/11/1

N2 - PURPOSE: To evaluate the prognostic relevance of CEACAM1 and sialyl Lewis X expression in adenocarcinomas of the lung.PATIENTS AND METHODS: Paraffin wax sections of 93 patients with adenocarcinomas of the lung who underwent surgery between 1990 and 1995 were immunohistochemically investigated using monoclonal anti-CEACAM1 and sialyl Lewis X antibodies. The clinical course of all patients was followed up for a minimum of 5 years.RESULTS: Sixty-one tumors were classified as CEACAM1-positive, and 32 were classified as CEACAM1-negative. Patients with CEACAM1-positive tumors had a significantly poorer overall (P =.00025) and relapse-free (P =.00029) survival than those with CEACAM1-negative tumors. Only three patients did not express the sialyl Lewis X glycotope, whereas 90 tumors (97%) were sialyl Lewis X-positive. In multivariate Cox regression analysis, next to tumor stage and sex, only the expression of CEACAM1 was a significant independent prognostic factor for survival.CONCLUSION: Expression of CEACAM1 was an independent prognostic factor in our patient population and can be used to stratify patients with adenocarcinomas of the lung into low-risk and high-risk groups. In contrast, the expression of sialyl Lewis X was of no prognostic relevance because it was expressed in 97% of all investigated tumors, and most likely has no influence on the function of CEACAM1 in this tumor entity.

AB - PURPOSE: To evaluate the prognostic relevance of CEACAM1 and sialyl Lewis X expression in adenocarcinomas of the lung.PATIENTS AND METHODS: Paraffin wax sections of 93 patients with adenocarcinomas of the lung who underwent surgery between 1990 and 1995 were immunohistochemically investigated using monoclonal anti-CEACAM1 and sialyl Lewis X antibodies. The clinical course of all patients was followed up for a minimum of 5 years.RESULTS: Sixty-one tumors were classified as CEACAM1-positive, and 32 were classified as CEACAM1-negative. Patients with CEACAM1-positive tumors had a significantly poorer overall (P =.00025) and relapse-free (P =.00029) survival than those with CEACAM1-negative tumors. Only three patients did not express the sialyl Lewis X glycotope, whereas 90 tumors (97%) were sialyl Lewis X-positive. In multivariate Cox regression analysis, next to tumor stage and sex, only the expression of CEACAM1 was a significant independent prognostic factor for survival.CONCLUSION: Expression of CEACAM1 was an independent prognostic factor in our patient population and can be used to stratify patients with adenocarcinomas of the lung into low-risk and high-risk groups. In contrast, the expression of sialyl Lewis X was of no prognostic relevance because it was expressed in 97% of all investigated tumors, and most likely has no influence on the function of CEACAM1 in this tumor entity.

KW - Adenocarcinoma

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal

KW - Antigens, CD

KW - Antigens, CD15

KW - Antigens, Differentiation

KW - Carcinoma, Non-Small-Cell Lung

KW - Cell Adhesion Molecules

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Immunohistochemistry

KW - Lewis Blood-Group System

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Oligosaccharides

KW - Prognosis

KW - Retrospective Studies

KW - Risk Factors

KW - Survival Analysis

KW - Tumor Markers, Biological

M3 - SCORING: Journal article

C2 - 12409325

VL - 20

SP - 4279

EP - 4284

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 21

ER -